RT Journal Article
SR Electronic
T1 A Novel COVID-19 Early Warning Tool: Moore Swab Method for Wastewater Surveillance at an Institutional Level
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20238006
DO 10.1101/2020.12.01.20238006
A1 Pengbo Liu
A1 Makoto Ibaraki
A1 Jamie VanTassell
A1 Kelly Geith
A1 Matthew Cavallo
A1 Rebecca Kann
A1 Christine Moe
YR 2020
UL http://medrxiv.org/content/early/2020/12/03/2020.12.01.20238006.abstract
AB SARS-CoV-2 is a respiratory virus but it is also detected in a significant proportion of fecal samples of COVID-19 cases. Recent studies have shown that wastewater surveillance can be a low-cost tool for management of COVID-19 pandemic and tracking COVID-19 outbreaks in communities but most studies have been focusing on sampling from wastewater treatment plants. Institutional level of wastewater surveillance may serve well for early warning purposes since cases can be tracked and immediate action can be executed in the event of positive signal. In this study, a novel Moore swab method was developed and used for wastewater surveillance of COVID-19 at institutional level. Among the 219 swab samples tested, 28 (12.8%) swabs collected from the three campuses and two buildings were positive for SARS-CoV-2. Further individual clinical diagnosis validated the wastewater results and indicated that this method was sensitive enough to detect 1-2 cases in a building. In addition, comparison between grab and Moore swab methods from the hospital sewage line indicated that Moore swab method was more sensitive than the grab sampling method. These results suggest that the Moore swab is a sensitive, practical, and easy to use early warning tool for COVID-19 surveillance especially in low-resource settings and at an early stage of infection in communities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEmory University Internal Funding Rollins School of Public Health (RSPH) rapid COVID-19 pilot grantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB involvesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll our data are available upon request